Cargando…
Insights into biological therapeutic strategies for COVID-19
The worldwide pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late December 2019 requires the urgent development of therapeutic options. So far, numerous studies have investigated and uncovered the underlyin...
Autores principales: | Tian, Xiaolong, Li, Cheng, Wu, Yanling, Ying, Tianlei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860937/ http://dx.doi.org/10.1016/j.fmre.2021.02.001 |
Ejemplares similares
-
Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections
por: Huang, Keke, et al.
Publicado: (2022) -
Inhalable antibodies for the treatment of COVID-19
por: Yang, Zhenlin, et al.
Publicado: (2022) -
Single-Domain Antibodies As Therapeutics against Human Viral Diseases
por: Wu, Yanling, et al.
Publicado: (2017) -
The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022) -
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
por: Feng, Gong, et al.
Publicado: (2020)